The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled ``Bacillus Calmette-Gu[eacute]rin (BCG)-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment.'' This guidance was developed to assist in the development of drugs and biologics for patients with a form of bladder cancer that is not amenable to currently available medical therapy and remains an unmet medical need. This guidance finalizes the draft guidance of the same name issued on November 18, 2016.
Document
Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled ``Bacillus Calmette-Gu[eacute]rin (BCG)-Unresponsive Nonmuscl...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 6195
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment; Guidance for Industry; Availability,” thefederalregister.org (February 13, 2018), https://thefederalregister.org/documents/2018-02871/bacillus-calmette-gu-rin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and-biologics-for-treatment-gui.